Bausch + Lomb (NYSE:BLCO) Price Target Lowered to $18.00 at Stifel Nicolaus

Bausch + Lomb (NYSE:BLCO) had its price target decreased by analysts at Stifel Nicolaus from $19.00 to $18.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 3.42% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Morgan Stanley cut shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Monday, December 2nd. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Evercore ISI upgraded Bausch + Lomb from an “in-line” rating to an “outperform” rating and increased their target price for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Bausch + Lomb in a research note on Thursday, December 12th. Finally, Royal Bank of Canada increased their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb presently has an average rating of “Hold” and a consensus target price of $20.33.

Bausch + Lomb Trading Down 0.3 %

NYSE BLCO opened at $17.41 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. Bausch + Lomb has a one year low of $13.16 and a one year high of $21.69. The company’s 50 day moving average price is $18.41 and its 200 day moving average price is $18.14. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -16.58, a PEG ratio of 2.17 and a beta of 0.47.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the firm posted $0.22 EPS. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. On average, sell-side analysts predict that Bausch + Lomb will post 0.6 EPS for the current year.

Hedge Funds Weigh In On Bausch + Lomb

A number of large investors have recently bought and sold shares of BLCO. Barclays PLC bought a new position in shares of Bausch + Lomb during the third quarter worth about $5,797,000. Quadrature Capital Ltd bought a new position in Bausch + Lomb in the 3rd quarter worth about $526,000. River Road Asset Management LLC increased its stake in shares of Bausch + Lomb by 4.4% in the third quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock valued at $38,974,000 after purchasing an additional 85,987 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Bausch + Lomb during the third quarter valued at approximately $957,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Bausch + Lomb during the second quarter worth approximately $580,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.